Abstract:
The present invention relates to a use of manufacturing of a bispecific chimeric protein including DARPin (bispecific antibody zygocyte). The bispecific chimeric protein manufactured by using DARPin has reduced side effects (agonism) and/or has the increased effects. Provided in an embodiment of the present invention is a bispecific chimeric protein which includes (a) DARPin and (b) an antibody (for example, an antibody of an lgG form), an antibody fragment (an antigen-binding fragment, for example an antibody of scFv-Fc form), or a combination of the same. Provided in another embodiment is a method for manufacturing a bispecific chimeric protein which comprises the step of connecting (a) DARPin to (b) an antibody (for example, an antibody of an lgG form), an antibody fragment (for example, an antibody of scFv-Fc form), or a combination of the same.
Abstract:
Provided are a composition for removing a target cell membrane protein, an anticancer composition including the same as an active ingredient, and method for removing a cell membrane protein using the same, wherein the composition for removing a target cell membrane protein includes a double bond molecule having a first bonding domain bonded to a driver cell membrane protein and a second bonding domain bonded to a target cell membrane protein.
Abstract:
c-Met 및 EGFR 이중저해제및 IGF-1R 저해제를유효성분으로포함하는암의예방및/또는치료를위한병용투여용약학조성물, IGF-1R 저해제의항 c-Met 및 EGFR 이중저해제효능증진(저항성극복) 용도, 및 c-Met 및 EGFR 이중저해제에대한저항성마커로서의 IGF-1R의용도가제공된다.